Krystal Biotech, Inc.
KRYS
$180.30
-$3.62-1.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 45.48M | 27.18M | 15.57M | 932.00K | 8.69M |
| Total Depreciation and Amortization | 455.00K | 529.00K | 1.49M | 742.00K | 1.12M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.57M | 12.95M | 12.07M | 7.91M | 8.98M |
| Change in Net Operating Assets | -5.66M | 18.20M | -33.29M | 6.30M | -26.02M |
| Cash from Operations | 52.84M | 58.86M | -4.17M | 15.89M | -7.23M |
| Capital Expenditure | -801.00K | -1.05M | -1.13M | -1.26M | -1.85M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -82.98M | -33.28M | -18.22M | -24.72M | -8.31M |
| Cash from Investing | -83.78M | -34.33M | -19.35M | -25.98M | -10.16M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.43M | 3.37M | 10.64M | 15.97M | 2.62M |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -5.39M | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.43M | 3.37M | 10.64M | 10.58M | 2.62M |
| Foreign Exchange rate Adjustments | -594.00K | 286.00K | -337.00K | 187.00K | -140.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -29.10M | 28.18M | -13.22M | 678.00K | -14.91M |
